CTGFL is a member of the connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (nov) (CCN) family and is upregulated in the mouse mammary epithelial cell line C57MG transformed by Wnt-1 and in several non-invasive human breast tumor cell lines. CTGFL expression is enhanced by important modulators of human breast cancer cell proliferation such as estrogen, progesterone and epidermal growth factor (EGF) in MCF-7 cells. These effects, inhibited by appropriate antagonists, indicate that steroids and growth factor-induced upregulation of CTGFL may be mediated through receptors. CTGFL gene may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. Its expression in colon tumors is reduced while the other two CTGFL members are overexpressed in colon tumors. It is expressed at high levels in bone tissue, and may play an important role in modulating bone turnover.
Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.
Recommended Dilutions:
ELISA: 0.05-0.2ug/ml
Western Blot: 0.1-1ug/ml
Optimal dilutions to be determined by the researcher.
Hybridoma:
Sp2/0-Ag14 myeloma cells with spleen cells from Balb/c mice.
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Quick Search
Products 
